These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 23440663)

  • 1. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    Vincent Rajkumar S
    Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2011 Jan; 86(1):57-65. PubMed ID: 21181954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2012 Jan; 87(1):78-88. PubMed ID: 22180161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2016 Jul; 91(7):719-34. PubMed ID: 27291302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
    Rajkumar SV
    Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2024 Sep; 99(9):1802-1824. PubMed ID: 38943315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of newly diagnosed myeloma.
    Palumbo A; Rajkumar SV
    Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
    Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
    Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.